PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: NeonDrum Ltd

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Pharmaceutical Regulatory Affairs Specialist ELC Group Establishes Global HQ in Cambridge, UK - Opening of new global base follows year of exceptional revenue growth - ELC-Group.com
Pharmaceutical Regulatory Affairs Specialist ELC Group Establishes Global HQ in Cambridge, UK

 

NewswireToday - /newswire/ - Reading, Berkshire, United Kingdom, 2012/02/08 - Opening of new global base follows year of exceptional revenue growth - ELC-Group.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

ELC GROUP, the pan-European pharmaceutical regulatory affairs organisation, today formally announces that it has established its global headquarters in Cambridge, UK. The opening of the new global HQ follows a year of exceptional revenue growth for ELC Group, and strengthens ELC Group’s ability to serve customers across its major global regions. The Cambridge operation is being headed by Anna Szymanska, General Manager Regulatory Affairs.

Last year, ELC Group announced a doubling of its revenues for the first quarter of 2011, and the company has seen demand soar for its regulatory affairs consulting and commercialisation services across key global markets. Customer demand has been particularly strong for ELC Group’s pharmacovigilance solutions and regulatory submission services. ELC Group’s specialist services – delivered by highly-skilled teams of regulatory affairs professionals – have experienced exponential growth in strategic territories including India and China, leading to the establishment of a new operational headquarters for the high-growth organisation.

ELC GROUP has previously announced its intention to explore acquisition targets in the speciality CROs and services companies’ landscape, and will lead its continued market expansion from the newly-opened UK base. ELC Group is also exploring commercial opportunities in the South Asia market and is planning to implement expansion plans in the region over the coming months. To support ELC Group’s growth strategy, the new global headquarters will host a core team of senior regulatory affairs experts and business development personnel, with plans to recruit additional experienced regulatory affairs staff by the end of the year.

Marco Rubinstein, CEO of ELC Group, comments: “In tough market conditions, we have enjoyed a year of truly outstanding revenue growth. This really demonstrates the value our global customers are deriving from our core offering, and provides an excellent platform for the strategic plans we have in place to expand the breadth and depth of ELC Group’s capabilities.” He continues: “The establishment of our new global headquarters provides us with an optimal location from which to execute our growth ambitions and cement our leadership position in the regulatory affairs service market.”

ELC Group helps pharmaceutical clients expedite time-to-market through a broad range of development capabilities, integrated advanced technologies, regulatory affairs consulting, and commercialisation services. ELC Group delivers its customised solutions through four core business segments: Regulatory Affairs Services; Medical Devices; EU REACH (Registration, Evaluation and Authorisation of Chemicals) Regulation Services; and Corporate Languages Solutions (Translations, Design, DTP, Localisation).

NOTE: The statements made in this Press Release may contain forward-looking statements that involve a number of risks and uncertainties.

Press contacts
Akhil Jain, ELC Group
P: +420 22 491 00 00 - E: ajain[.]elc-group.com.

About ELC Group
ELC Group (elc-group.com) is a leading global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries as well as REACH services to the Chemical industry. It helps companies that lack the resource (skills and knowledge) to cost effectively deliver regulatory affairs.

ELC Group provides full-service, multi-lingual consulting and cost-effective solutions to regulatory approvals using experts with in-depth knowledge and experience throughout the world. The team ranges from former FDA investigators to individuals with over 30 years of industry experience with broad capabilities. This includes integrated advanced technologies, regulatory affairs consulting and commercialisation services.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: NeonDrum Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Pharmaceutical Regulatory Affairs Specialist ELC Group Establishes Global HQ in Cambridge, UK

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Liz Hartney - NeonDrum.com 
+44(0)75 1051 8732 nicky[.]evokedset.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any NeonDrum Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From NeonDrum Ltd / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Triggr & Bloom

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)